Companies /Healthcare

Relmada Therapeutics Inc

NASDAQ: RLMD Biotechnology
$2.62
▼ $0.49 (−15.76%) today
Markets closed · 4:43am ET

RLMD at a Glance

Valuation
Market cap
$331.8M
Profitability
EPS (TTM)
$-0.73
Price
52-week range
$3 – $8
Street target
$10.75

Headquartered in Coral Gables, FL Fiscal year ends December NASDAQ: RLMD relmada.com

About Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company with no product revenue that develops therapies in oncology and central nervous system disorders. Its lead candidate, NDV-01, is a sustained-release intravesical co-formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC). NDV-01 forms a soft matrix in the bladder that releases drug for up to 10 days. It is designed as a ready-to-use, in-office treatment administered in under 5 minutes without anesthesia or specialized pharmacy preparation, targeting community urology practices. Its pending patent applications could provide protection to 2047 if issued. NDV-01 has shown high complete response rates in an ongoing Phase 2 study. It is headed into the FDA-aligned Phase 3 SPECTRUM program, which has two independent registrational pathways: second-line BCG-unresponsive high-risk NMIBC and adjuvant intermediate-risk NMIBC. The company's second candidate, sepranolone, is a GABA-A modulating steroid antagonist (isoallopregnanolone) being developed for compulsivity-related disorders. A Phase 2b trial in Prader-Willi Syndrome is planned. Relmada funds development through equity financing and holds about $202.1 million in cash and short-term investments, which management expects to fund operations through 2029. Updated

RLMD Coverage

Frequently Asked Questions

What does Relmada Therapeutics do?

Relmada Therapeutics is a clinical-stage biotechnology company with no product revenue that develops therapies in oncology and central nervous system disorders. Its lead candidate, NDV-01, is a sustained-release intravesical co-formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC).

What is the RLMD stock price target?

The Wall Street consensus 12-month price target for RLMD is $10.75.